Safety and Feasibility of ADRCs Treatment To Patients With Thermal Wounds

NCT ID: NCT03435172

Last Updated: 2019-09-25

Basic Information

• Recruitment Status: SUSPENDED
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-04-01
• Study Completion Date: 2021-07-31

Brief Summary

The primary objective of the protocol is to evaluate preliminary safety and feasibility of ADRCs via intravenous delivery in the treatment of deep partial and full thickness thermal wounds.

Detailed Description

The RELIEF Trial is a prospective, open-label, parallel group, usual care controlled, multi-center randomized (2:1, active: usual care alone) safety and feasibility study targeting thermal burns. Subjects will have at least one deep partial or full thickness burn wounds of > 250 cm2 that is to be autografted with a split thickness meshed skin graft (STSG). Subjects randomized to ADRCs will undergo small volume fat harvest (100 to 150 mL) performed at initiation of general anesthesia for scheduled burn surgery followed by intravenous delivery of ADRCs within 4 hours following surgery. The lipoaspirate will be processed in the Celution® System to isolate and concentrate ADRCs.

Following informed consent and initial screening assessments, eligible subjects will undergo pre-operative testing. On the procedure day, subjects will be randomized to ADRCs (with usual care) or usual care alone. Low volume lipoharvest will only be performed on subjects randomized to ADRCs in order to obtain 100-150 mL lipoaspirate, which will then be transferred to the Celution® System for processing to isolate and concentrate ADRCs for same-day administration. All treatment will be delivered in a total volume of 10 mL which will be delivered by slow intravenous administration into a peripheral vein.

Following surgery, subjects will be evaluated at first dressing change, day 10 (±2) (only if wound dressing change planned) and weeks 2 (±3 days), 3 (±3 days), 4 (±3 days), 8 (±7 days), 12 (±14 days), 26 (±14 days), and 52(±21 days).

The 1st 5 subjects enrolled in active treatment will be observed for adverse events over a 7 day period. If no SAEs occur during that period, for that individual subject, the next subject enrolled in active treatment may be entered with the same 7 day observation period. The safety results of the first 5 subjects will be reviewed by the DMC and their evaluation will be used in conjunction with the clinical data collected to date, and if appropriate, to potentially remove the staggering approach to the study. Enrollment after the first 5 subjects may continue only after the DMC has completed its safety review and recommends continuation.

Conditions

Thermal Burn

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Group

Device-ADRCs intravenously infusion 20 million ADRCs generated by Celution device will be intraveously infused through peripheral vein. Standard care of split thickness meshed skin graft (STSG) will be used.

Group Type: EXPERIMENTAL

Device-ADRCs intravenously infusion

Intervention Type: DEVICE

Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.

Usual Care

Standard care of split thickness meshed skin graft (STSG) will be used.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Device-ADRCs intravenously infusion

Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Males or females age ≥ 18 to ≤ 65
• BMI > 20 kg/m2
• Burn TBSA 20% - 50%
• At least one deep partial thickness and/or full thickness thermal burn ≥ 250 cm2 on the arms, legs, back, abdomen or chest that is anticipated to be covered with autologous meshed STSG meshed and that has not been treated previously with a biologic dressing such as Alloderm® or Integra®
• Ability to safely undergo tissue harvest that is anticipated to yield >150mL of adipose tissue at a site that is free from infection
• Donor site availability for skin graft harvest
• Able to provide written informed consent signed by either the patient or their legally authorized representative
• Women and men of child-bearing potential agreeing to use contraception during the study. Acceptable methods include surgical sterility, IUDs, hormonal contraception or double barrier methods

Exclusion Criteria

• Subjects with burns > 3rd degree (i.e. involvement of deeper tissues, such as muscle, tendons, or bone)
• Subjects with electrical or chemical burns
• Subjects with significant inhalation injuries necessitating intubation and mechanical ventilation or requiring > 50% FI02 on a continuous basis to maintain oxygenation (02 sat > 90%)
• In the opinion of treating physician, patient not expected to survive beyond 30 days
• Pre-existing condition requiring current use of immunosuppressive medication or systemic steroids
• Pregnant or lactating status. Pregnancy as determined by a positive pregnancy test at screening or baseline
• Known history of HIV infection, or active Hepatitis B or active Hepatitis C infection
• Cancer requiring chemotherapy or radiation within previous 6 months or resection within the last 5 years (other than basal cell carcinoma)
• Known chronic renal failure (serum creatinine > 2 mg/dL) or chronic liver disease
• Pre-existing medical conditions that would interfere with wound healing (i.e.diabetic patients with Hemoglobin A1c test result ≥8%, malignancy, autoimmune disease)
• Subjects with psychiatric conditions that are anticipated to result in protocol noncompliance
• Chronic illicit drug or alcohol abuse that is anticipated to interfere with patient compliance with the protocol
• Participation in another clinical trial within 60 days of the screening visit

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cytori Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marc H Hedrick, MD

Role: PRINCIPAL_INVESTIGATOR

Cytori therapeutics Inc

Locations

Maricopa IHS

Phoenix, Arizona, United States

Univeristy of Southern California

Los Angeles, California, United States

MedStar Health Research Institute

Washington D.C., District of Columbia, United States

University of Florida

Gainesville, Florida, United States

Ohio State University

Columbus, Ohio, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Other Identifiers

RELIEF

Identifier Type: -

Identifier Source: org_study_id